POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a radiopharmaceutical company developing targeted cancer treatments using radioligand technology. The company went public in 2021 through a business combination with GX Acquisition Corp. II, a healthcare-sector SPAC. The June 2022 Form 8-K was filed during its post-merger operating phase as POINT Biopharma advanced oncology-focused radiopharmaceutical candidates through clinical development, with manufacturing operations spanning the United States and Canada. The company continued as an independent public issuer through this period before being acquired by Eli Lilly and Company in 2023. Sign up at SpacDesk for complete filing histories, SPAC deal data, and real-time analytics on PNT and the broader market.